Skip to main content

Table 5 Risks of death and hospitalisations: subgroup analysis in patients 65 years or older

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event Aspart vs lispro Glulisine vs lispro Glulisine vs aspart
Total Mortality 1.10 [0.84, 1.44] 0.61 [0.37, 1.02] 0.56 [0.36, 0.87]
CHD 1.02 [0.83, 1.26] 1.09 [0.78, 1.52] 1.06 [0.81, 1.40]
Fatal CHD 1.18 [0.74, 1.89] 0.85 [0.38, 1.90] 0.72 [0.37, 1.40]
CVD 0.95 [0.78, 1.14] 0.98 [0.72, 1.33] 1.04 [0.80, 1.34]
Fatal CVD 1.15 [0.75, 1.78] 0.76 [0.36, 1.61] 0.66 [0.35, 1.23]
Stroke 0.86 [0.56, 1.33] 0.28 [0.11, 0.71]* 0.32 [0.14, 0.76]*
Heart Failure 0.97 [0.75, 1.25] 0.74 [0.47, 1.18] 0.77 [0.51, 1.15]
Kidney Failure 0.78 [0.58, 1.06] 0.68 [0.38, 1.22] 0.87 [0.52, 1.46]
Hypoglycaemia 2.37 [1.07, 5.25]* 3.24 [1.12, 9.42]* 1.37 [0.65, 2.88]
Hyperglycaemia 4.67 [1.49, 14.65]* 0.39 [0.09, 1.64] 0.39 [0.09, 1.64]
  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05